THALES
8.6.2021 09:02:12 CEST | Business Wire | Press release
The award winning* Cinterion® IoT Suite Connectivity Activation by Thales greatly simplifies and digitalises cellular connectivity and the daily operations of industrial IoT device manufacturers and service providers. Based on standard eSIM technology, the new solution eliminates the need for IoT service providers to setup and run complex eSIM Remote Subscription Provisioning (RSP) platforms. It uses a single IoT eSIM that works with whichever mobile operator is selected by the device manufacturer or IoT service provider. The solution also enables resilient device connectivity and lifecycle management over the multi-year life spans of industrial solutions thereby delivering a reduction in Total Cost of Ownership for customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210608005041/en/
By 2025, 75 billion IoT devices will be connected with a potential market value of around $1.6 trillion. This not only brings unprecedented business opportunities, but also challenges such as how to streamline supply chain logistics for smart devices.
The solution simplifies manufacturing processes and logistics : In fact, device manufacturers no longer need to produce multiple product variants for deployment with different Mobile Network Operators (MNOs) in different countries. One product now fits all MNO networks as the IoT eSIM embedded in the industrial device can connect to any MNO network worldwide.
Thales system shortens device installation: Thanks to a remote activation process, the IoT eSIM automatically downloads the MNO profile that best suits the device location and connects to the network according to the service providers’ pre-defined business rules.
The solution guarantees network resilience and longevity : As networks and IoT applications evolve, the solution ensures reliable connectivity and business continuity by automatically switching to back-up connectivity providers removing the need for physical device updates.
“Thales leverages its unique expertise of cellular network infrastructure and collaboration with more than 400 mobile operators to simplify industrial IoT connectivity.The Thales Connectivity solution offers all the benefits of digitalisation and eSIM technology for the industrial IoT sector. With more than 25 years of constant innovation in IoT connectivity solutions, Thales enables the best total-cost-of-ownership and performance to its customers.” Frederic Deman, SVP of Analytics and IoT Solutions Business Line, at Thales.
“The IoT eSIM solution is a huge step forward for Aidon helping to ensure production flexibility and connectivity of our smart meters, even in rural areas, and all without the need for physical handling of SIMs,” said Petri Ounila, Director, IoT Devices, Aidon. “The solution co-developed with Thales provides a true operator selection and provisioning at any stage of the product lifetime. It is improving our ability to get smart meters connected, stay connected and adapt to new metering as-a-service business models.”
“The Thales Cinterion Connectivity Activation solution turns traditional methods of IoT device service provisioning and updating on its head, bringing new levels of service digitization, automation, Over-the-Air (OTA) management, and digital security to industrial IoT solutions” said Phil Sealy, Research Director at ABI Research . “Device manufacturers and service providers will no longer be tied to complex connectivity device design and logistics, thanks to a simplified and flexible approach. By easing the path to cellular connectivity and management, device manufacturers and service providers can redshift their focus toward innovation and scaling digital transformation for their customers.”
To learn more, join one of our virtual launch events on June 16 at 9:00 AM or 5:00 PM CEST.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.
PLEASE VISIT
Thales Group
Digital Identity & Security page
View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005041/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom